Abstract
Insights into immune-mediated thrombotic thrombocytopenic purpura (iTTP) pathophysiology have led to novel targeted therapies. Immunomodulatory strategies target anti-ADAMTS13 antibodies: rituximab is effective in inducing responses in refractory/relapsed TTP and increasing relapse-free survival; caplacizumab targets the von Willebrand factor–platelet interaction to hasten platelet count recovery and reduce mortality and TTP-related ischemic events. Bortezomib and recombinant ADAMTS13 are under investigation. This review examines how targeted therapies are disrupting current treatment paradigms to improve outcomes of iTTP.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 415-420 |
| Number of pages | 6 |
| Journal | Blood |
| Volume | 134 |
| Issue number | 5 |
| DOIs | |
| State | Published - Aug 1 2019 |
Bibliographical note
Funding Information:This work was supported by a Mentored Research Award from the Hemostasis and Thrombosis Research Society (S.C.). The funders had no role in preparation of the manuscript, or decision to publish.
Publisher Copyright:
© 2019 by The American Society of Hematology.
